Chairman:  Joe Pitts (PA-16)
Public health and quarantine; hospital construction; mental health; biomedical research and development; health information technology, privacy, and cybersecurity; public health insurance (Medicare, Medicaid) and private health insurance; medical malpractice and medical malpractice insurance; the regulation of food, drugs, and cosmetics; drug abuse; the Department of Health and Human Services; the National Institutes of Health; the Centers for Disease Control; Indian Health Service; and all aspects of the above-referenced jurisdiction related to the Department of Homeland Security.



Joe Pitts (PA), Chairman
Brett Guthrie (KY), Vice Chairman
Ed Whitfield (KY)
John Shimkus (IL)
Tim Murphy (PA)
Michael C. Burgess, M.D. (TX)
Marsha Blackburn (TN)
Cathy McMorris Rodgers (WA)
Leonard Lance (NJ)
Morgan Griffith (VA)
Gus Bilirakis (FL)
Billy Long (MO)
Renee Ellmers (NC)
Larry Bucshon (IN)
Susan Brooks (IN)
Chris Collins (NY)
Joe Barton (TX)
Fred Upton (MI) (Ex Officio)


Gene Green (TX), Ranking Member
Eliot L. Engel (NY)
Lois Capps (CA)
Jan Schakowsky (IL)
G. K. Butterfield (NC)
Kathy Castor (FL)
John Sarbanes (MD)
Doris O. Matsui (CA)
Ben Ray Lujan (NM)
Kurt Schrader (OR)
Joseph P. Kennedy, III (MA)
Tony Cardenas (CA)
Frank Pallone, Jr. (NJ) (Ex Officio)

July 8, 2015 | Blog Post

Rare Disease Advocate Noah Coughlan Completes his #Run4Rare Across America Days Before House Vote on 21st Century Cures

July 7, 2015 | ICYMI

Dear Colleague: 21st Century Cures Act is Curing American Entitlement Sickness with Innovation

July 7, 2015 | Press Release

WASHINGTON, DC – Bipartisan leaders of the House Energy and Commerce Committee today sent a letter to Food and Drug Administration Acting Commissioner Dr. Stephen Ostroff regarding the labeling of certain opioids, particularly the discrepancy between Extended Release and Long-Acting (ER/LA) opioid analgesics and Immediate Release (IR) opioid analgesics.

July 7, 2015 | Letter

Excerpt: In 2013, FDA adopted labeling changes affecting Extended Release and Long-Acting (ER/LA) opioid analgesics, requiring manufacturers to adopt the most restrictive language that can be found in drug labeling, a ‘black box’ warning about their potential for abuse, the risk of fatal overdose, and a warning that maternal use of these products during pregnancy can result in neonatal opioid w

July 7, 2015 | Blog Post

A Pint-Sized Reminder Of Why We Need #Cures2015

This week the House of Representatives will consider H.R. 6, the 21st Century Cures Act. The Energy and Commerce Committee approved this legislation by a vote of 51-0 on May 21, 2015. That day, there was a very special guest in the audience. 

July 7, 2015 | Blog Post

Physicians, Thought Leaders, and Advocates Line Up Behind 21st Century Cures